Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Comparative gene expression profiles induced by PPAR{gamma} and PPAR{alpha}/{gamma} agonists in rat hepatocytes

Journal Article · · Toxicology and Applied Pharmacology
 [1];  [2];  [3];  [1];  [2]
  1. UMR INSERM U991, Faculte des Sciences Pharmaceutiques et Biologiques, 35043 Rennes (France)
  2. Biologie Servier, 45520 Gidy (France)
  3. Institut de Recherches Servier, 92400 Courbevoie (France)

Species-differential toxic effects have been described with PPAR{alpha} and PPAR{gamma} agonists between rodent and human liver. PPAR{alpha} agonists (fibrates) are potent hypocholesterolemic agents in humans while they induce peroxisome proliferation and tumors in rodent liver. By contrast, PPAR{gamma} agonists (glitazones) and even dual PPAR{alpha}/{gamma} agonists (glitazars) have caused idiosyncratic hepatic and nonhepatic toxicities in human without evidence of any damage in rodent during preclinical studies. The mechanisms involved in such differences remain largely unknown. Several studies have identified the major target genes of PPAR{alpha} agonists in rodent liver while no comprehensive analysis has been performed on gene expression changes induced by PPAR{gamma} and dual PPAR{alpha}/{gamma} agonists. Here, we investigated transcriptomes of rat hepatocytes after 24 h treatment with two PPAR{gamma} (troglitazone and rosiglitazone) and two PPAR{alpha}/{gamma} (muraglitazar and tesaglitazar) agonists. Although, hierarchical clustering revealed a gene expression profile characteristic of each PPAR agonist class, only a limited number of genes was specifically deregulated by glitazars. Functional analyses showed that many genes known as PPAR{alpha} targets were also modulated by both PPAR{gamma} and PPAR{alpha}/{gamma} agonists and quantitative differences in gene expression profiles were observed between these two classes. Moreover, most major genes modulated in rat hepatocytes were also found to be deregulated in rat liver after tesaglitazar treatment. Taken altogether, these results support the conclusion that differential toxic effects of PPAR{alpha} and PPAR{gamma} agonists in rodent liver do not result from transcriptional deregulation of major PPAR target genes but rather from qualitative and/or quantitative differential responses of a small subset of genes.

OSTI ID:
21587775
Journal Information:
Toxicology and Applied Pharmacology, Journal Name: Toxicology and Applied Pharmacology Journal Issue: 1 Vol. 254; ISSN TXAPA9; ISSN 0041-008X
Country of Publication:
United States
Language:
English

Similar Records

Effects of the PPAR{gamma} agonist troglitazone on endothelial cells in vivo and in vitro: Differences between human and mouse
Journal Article · Fri May 15 00:00:00 EDT 2009 · Toxicology and Applied Pharmacology · OSTI ID:21272557

Selective modulation of promoter recruitment and transcriptional activity of PPAR{gamma}
Journal Article · Thu Dec 20 23:00:00 EST 2007 · Biochemical and Biophysical Research Communications · OSTI ID:21033015

Statins and PPAR{alpha} agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment
Journal Article · Mon Oct 31 23:00:00 EST 2005 · Toxicology and Applied Pharmacology · OSTI ID:20722022